- Home
- ADIL vs APRE Comparison
ADIL vs APRE Comparison
Compare ADIL & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADIL
- APRE
- Stock Information
- Founded
- ADIL 2010
- APRE 2006
- Country
- ADIL United States
- APRE United States
- Employees
- ADIL N/A
- APRE N/A
- Industry
- ADIL Biotechnology: Pharmaceutical Preparations
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ADIL Health Care
- APRE Health Care
- Exchange
- ADIL Nasdaq
- APRE Nasdaq
- Market Cap
- ADIL 7.7M
- APRE 8.3M
- IPO Year
- ADIL 2018
- APRE 2019
- Fundamental
- Price
- ADIL $0.40
- APRE N/A
- Analyst Decision
- ADIL Strong Buy
- APRE Strong Buy
- Analyst Count
- ADIL 2
- APRE 1
- Target Price
- ADIL $4.75
- APRE $20.00
- AVG Volume (30 Days)
- ADIL 745.4K
- APRE 43.2K
- Earning Date
- ADIL 11-12-2025
- APRE 11-06-2025
- Dividend Yield
- ADIL N/A
- APRE N/A
- EPS Growth
- ADIL N/A
- APRE N/A
- EPS
- ADIL N/A
- APRE N/A
- Revenue
- ADIL N/A
- APRE $841,012.00
- Revenue This Year
- ADIL N/A
- APRE N/A
- Revenue Next Year
- ADIL N/A
- APRE N/A
- P/E Ratio
- ADIL N/A
- APRE N/A
- Revenue Growth
- ADIL N/A
- APRE N/A
- 52 Week Low
- ADIL $0.22
- APRE $1.37
- 52 Week High
- ADIL $1.30
- APRE $5.01
- Technical
- Relative Strength Index (RSI)
- ADIL 58.88
- APRE 43.18
- Support Level
- ADIL $0.37
- APRE $1.44
- Resistance Level
- ADIL $0.41
- APRE $1.57
- Average True Range (ATR)
- ADIL 0.02
- APRE 0.07
- MACD
- ADIL 0.01
- APRE 0.01
- Stochastic Oscillator
- ADIL 75.00
- APRE 45.20
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.